Valuation: China Shineway Pharmaceutical Group Limited

Market Cap 545.3Cr 640.2Cr 82Cr 74Cr 69Cr 62Cr 117Cr 7.56TCr 122.96Cr 834.41Cr 331.64Cr 4.13TCr 306.5Cr 300.04Cr 13TCr P/E 2026 *
6.97x
P/E 2027 * 6.46x
Enterprise Value 545.3Cr 640.2Cr 82Cr 74Cr 69Cr 62Cr 117Cr 7.56TCr 122.96Cr 834.41Cr 331.64Cr 4.13TCr 306.5Cr 300.04Cr 13TCr EV / Sales 2026 *
2.18x
EV / Sales 2027 * 2.11x
Free-Float
33.69%
Yield 2026 *
-
Yield 2027 * -
06/11 China Shineway Pharmaceutical Group Limited Reports Unaudited Group Turnover Results for the Nine Months Ended 30 September 2026 CI
30/10 China Shineway Pharmaceutical Group Limited Announces Appointment of Kang Limin as Executive Director, Effective November 1, 2026 CI
29/09 China Shineway Pharmaceutical Group Limited Announces Board and Committee Changes, Effective 1 October 2026 CI
18/09 China Shineway Pharmaceutical Group Limited Declares Special Interim Dividend in Respect of the Fiscal Year Ending 31 December 2026, Payable on 15 October 2026 CI
27/08 China Shineway Pharmaceutical Group Limited Reports Earnings Results for the Half Year Ended June 30, 2026 CI
27/08 China Shineway Pharmaceutical Group Limited Declares Second Interim Dividend in Respect of the Fiscal Year Ended December 31, 2026, Payable on 25 September 2026 CI
07/05 China Shineway Pharmaceutical's Turnover Slides 18% in Q1 MT
07/05 China Shineway Pharmaceutical posts Q1 turnover of RMB624 mln RE
07/05 China Shineway Pharmaceutical Group Limited Reports Unaudited Turnover Results for the First Quarter Ended 31 March 2026 CI
28/03 China Shineway Pharmaceutical Group Limited Reports Earnings Results for the Full Year Ended December 31, 2025 CI
27/03 China Shineway Pharmaceutical declares 2026 first interim dividend RMB43 cents per share RE
27/03 China Shineway Pharma's Profit Climbs 13% in 2025 MT
27/03 China Shineway Pharmaceutical Group Limited Approves Dividend for First Interim Dividend in Respect of the Fiscal Year Ending 31 December 2026, Payable on May 19, 2026 CI
1 day+4.44%
1 week+11.15%
Current month+12.92%
1 month+13.91%
3 months+6.00%
6 months-1.22%
Current year-1.45%
1 week 7.56
Extreme 7.56
8.5
1 month 7.18
Extreme 7.185
8.5
Current year 7.12
Extreme 7.12
10.47
1 year 7.12
Extreme 7.12
10.47
3 years 6.61
Extreme 6.61
10.76
5 years 4.63
Extreme 4.63
10.76
10 years 4.6
Extreme 4.6
18.54
Manager TitleAgeSince
Investor Relations Contact 60 -
Sales & Marketing 46 01/12/2019
Comptroller/Controller/Auditor 53 01/02/2011
Director TitleAgeSince
Chairman 70 14/08/2002
Director/Board Member 58 -
Director/Board Member 50 01/10/2020
Date Insider Type Main position Quantity % Market Cap. Importance
31/10/22 Other

Director

2,80,000 0.0339%
Change 5-day change 1-year change 3-year change Capi.($)
+4.44%+11.15%-2.02%+22.47% 78Cr
+0.10%-6.42%+29.48%+126.05% 1,20400Cr
+1.75%-4.94%+33.76%+81.19% 64TCr
+1.80%-2.22%+25.73%+108.58% 50TCr
-0.60%-1.95%+27.26%+67.32% 38TCr
+1.28%-9.03%+41.54%+30.91% 33TCr
+0.41%-4.70%+27.23%+51.59% 28TCr
+0.81%-4.08%-1.74%+32.71% 27TCr
+0.55%-6.09%+30.13%+64.81% 24TCr
+0.86%-0.12%+34.32%+120.90% 21TCr
Average +1.13%-3.32%+24.57%+70.65% 41TCr
Weighted average by Cap. +0.74%-4.71%+28.50%+88.28%

Financials

2026 *2027 *
Net sales 250.46Cr 294.05Cr 38Cr 34Cr 31Cr 29Cr 54Cr 3.47TCr 56Cr 383.25Cr 152.32Cr 1.9TCr 140.78Cr 137.81Cr 5.96TCr 258.6Cr 303.61Cr 39Cr 35Cr 33Cr 30Cr 55Cr 3.59TCr 58Cr 395.71Cr 157.27Cr 1.96TCr 145.35Cr 142.29Cr 6.15TCr
Net income 82Cr 96Cr 12Cr 11Cr 10Cr 9.39Cr 18Cr 1.14TCr 19Cr 125.66Cr 50Cr 622.24Cr 46Cr 45Cr 1.95TCr 89Cr 103.95Cr 13Cr 12Cr 11Cr 10Cr 19Cr 1.23TCr 20Cr 135.49Cr 54Cr 670.89Cr 50Cr 49Cr 2.11TCr
Net Debt - -
Projected Income Statement - Annual - China Shineway Pharmaceutical Group Limited
Logo China Shineway Pharmaceutical Group Limited
China Shineway Pharmaceutical Group Ltd is an investment holding company primarily engaged in research and development, manufacturing and trading of Chinese pharmaceutical products. The Company’s product dosage forms include injections, soft capsules, granules, traditional Chinese medicine (TCM) granules, oral products and other dosage forms. The Company’s products include Qing Kai Ling Injection, Shen Mai Injection, Wu Fu Xin Nao Qing Soft Capsule, Qing Kai Ling Soft Capsule, Huamoyan Granule, Compound Licorice Tablet and other products, applied to influenza, cardio-cerebrovascular, respiratory system and other disease fields. The Company operates its business in mainland China and Hong Kong markets.
Employees
2,656
Date Price Change Volume
20/26/20 HK$8.475 +4.44% 34,90,000
19/26/19 HK$8.115 +2.53% 14,07,000
18/26/18 HK$7.915 +1.47% 11,75,000
17/26/17 HK$7.800 +0.39% 7,20,000
16/26/16 HK$7.770 +2.30% 19,37,000
Trader
Investor
-
Global
-
Quality
ESG MSCI
BBB
MarketScreener Ratings - China Shineway Pharmaceutical Group Limited
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
7.219CNY
Average target price
7.922CNY
Spread / Average Target
+9.75%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - China Shineway Pharmaceutical Group Limited
  1. Stock Market
  2. Stocks
  3. 2877 Stock